PV
PVCT.US Provectus Biopharmaceuticals Inc
- Market cap
- USD 17.9M
- P/E
- -
- P/B
- 5.44x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PVCT.US undervalued?
Graham numberThe Graham number of Provectus Biopharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Provectus Biopharmaceuticals Inc fundamental analysis
No fundamental analysis for Provectus Biopharmaceuticals Inc yet.
Provectus Biopharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and …
Full company profileProvectus Biopharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Provectus Biopharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - |
| Operating Income | -24.5M | -13.7M | -8.05M | -6.30M | -4.96M | -4.64M | -3.39M | -2.93M | -4.53M | -5.29M | -4.53M |
| EBITDA | - | -13.0M | -6.50M | -4.78M | -4.69M | -4.56M | -3.38M | -2.88M | -4.52M | -5.29M | -4.53M |
| Net Income | -24.4M | -13.5M | -8.15M | -6.92M | -6.68M | -5.54M | -3.55M | -3.10M | -4.76M | -5.51M | -4.72M |
| EPS | -0.07 | -0.04 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 5.61M | 3.44M | 1.99M | 1.48M | 589K | 3.51M | 2.04M | 1.45M | 1.01M | 698K | 467K |
| Total Liabilities | 2.14M | 13.5M | 19.4M | 25.5M | 30.8M | 7.70M | 8.27M | 9.04M | 6.98M | 7.00M | 7.15M |
| Shareholders' Equity | 3.47M | -10.0M | -17.4M | -24.1M | -30.2M | -4.19M | -6.23M | -7.59M | -5.96M | -6.30M | -6.66M |
| Cash & Short-term Investments | 1.17M | 106K | 51.0K | 591K | 97.2K | 683K | 21.6K | 76.6K | 307K | 251K | 181K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -21.9M | -10.3M | -5.20M | -6.19M | -4.09M | -1.01M | -3.04M | -2.57M | -3.28M | -3.33M | -2.10M |
| Capital Expenditure | 30.4K | 30.4K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -10.4M | -5.20M | -6.19M | -4.09M | -1.01M | -3.04M | -2.57M | -3.28M | -3.33M | -2.10M |
| Ratios | |||||||||||
| ROE | -704.1% | - | - | - | - | - | - | - | - | - | - |
| ROA | -435.3% | -393.4% | -410.1% | -468.7% | -1,133.3% | -157.7% | -174.5% | -214.1% | -473.3% | -789.3% | -1,010.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Provectus Biopharmaceuticals Inc dividends
Provectus Biopharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:300 on Apr 11, 2002.
Who owns Provectus Biopharmaceuticals Inc
- Insiders 7.48%
- Institutions 0.03%
- Public & others 92.49%
- Shares outstanding 420M
- Free float 389M
Provectus Biopharmaceuticals Inc company profile
- Company name
- Provectus Biopharmaceuticals Inc
- Ticker
- PVCT.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6
- Fiscal year end
- December
- Address
- 800 South Gay Street, Knoxville, TN, United States, 37929
- Phone
- 866 594 5999
- Website
- provectusbio.com
About Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It also has collaboration agreement with Bascom Palmer Eye Institute, and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Provectus Biopharmaceuticals Inc management
4- Mr. Edward V. Pershing CPACEO & Executive Chairman of Board · born 1953
- Mr. Dominic Rodrigues C.F.A.President & Executive Vice Chairman of the Board · born 1969
- Dr. Eric A. Wachter Ph.D.Co-Founder & CTO · born 1963
- Ms. Heather Raines CPAChief Financial Officer · born 1967